Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit

Rhea-AI Summary

Pharming (PHARM) will participate in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City.

Anurag Relan, M.D., Chief Medical Officer, will join a fireside chat on the hereditary angioedema (HAE) market at 1:50 pm ET / 19:50 CET. The event is invitation-only and gathers companies and investors focused on rare diseases. One-on-one meetings with Pharming management can be requested via investor@pharming.com or through an Oppenheimer representative.

Market Context

This announcement highlighted Pharming’s participation in a rare disease–focused Oppenheimer summit ...

Analysis

This announcement highlighted Pharming’s participation in a rare disease–focused Oppenheimer summit on December 11, 2025, including a fireside chat on the hereditary angioedema (HAE) market at 1:50 pm ET. It mainly signals investor-relations activity and engagement with specialized healthcare investors rather than a new clinical or financial milestone. Investors may watch for future updates that translate this increased visibility into measurable clinical, regulatory, or commercial progress.

Key Figures

Summit date: December 11, 2025 Fireside chat time (ET): 1:50 pm ET Fireside chat time (CET): 19:50 CET

3 metrics

Summit date December 11, 2025 Oppenheimer Movers in Rare Disease Summit

Fireside chat time (ET) 1:50 pm ET HAE market fireside chat

Fireside chat time (CET) 19:50 CET HAE market fireside chat

Key Terms

hereditary angioedema, HAE

2 terms

hereditary angioedema medical

"a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

HAE medical

"a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm"

Hereditary angioedema (HAE) is a rare genetic disorder that causes sudden, severe swelling in tissues such as the face, throat, abdomen and limbs due to abnormal control of blood vessel leakage. It matters to investors because HAE treatments, which can be life‑saving and are often taken long‑term, represent a specialized drug market with high per‑patient revenue and regulatory, pricing and reimbursement risks similar to other rare‑disease therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases.

Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm ET / 19:50 CET.

To schedule a one-on-one meeting with Pharming’s management team, please contact Investor Relations at investor@pharming.com or your Oppenheimer representative.

About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Investor Relations
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: investor@pharming.com

Media Relations
Global: Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
E: media.relations@pharming.com

U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
T: +1 (917) 882-9038

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

• Pharming Oppenheimer Movers in Rare Disease Conference_EN_08DEC25

FAQ

When will Pharming (PHARM) present at the Oppenheimer Movers in Rare Disease Summit?

Pharming will participate on December 11, 2025, with a fireside chat at 1:50 pm ET / 19:50 CET.

What topic will Pharming's Chief Medical Officer discuss at the PHARM presentation?

Anurag Relan, M.D., will discuss the hereditary angioedema (HAE) market during the fireside chat.

How can investors schedule a one-on-one meeting with Pharming (PHARM) at the December 11 summit?

Investors can request meetings by emailing investor@pharming.com or contacting their Oppenheimer representative.

Is the Oppenheimer Movers in Rare Disease Summit open to the public for the Pharming (PHARM) session?

No, the summit is invitation-only and targets companies and investors focused on rare diseases.

Which time zones are provided for Pharming's fireside chat at the PHARM event?

The fireside chat is listed as 1:50 pm ET and 19:50 CET on December 11, 2025.